Drugs / F-MISO
F-MISO
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01246869 | Mar 2013 → May 2014 | brain cancer | University of Utah | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03649880 | Jun 2019 → Jan 2029 expected | IDH-wildtype glioblastoma | OHSU Knight Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT04031534 | Mar 2019 → Aug 2021 | oropharynx squamous cell carcinoma | Centre Henri Becquerel | Completed | No outcome recorded |
| Phase 2 | NCT03303469 | Oct 2017 → Jan 2021 | hepatocellular carcinoma | University of Alabama at Birmingham | Terminated | No outcome recorded Stop: Enrollment |
| Phase not applicable1 trial | ||||||
| — | NCT02841332 | May 2013 → Sep 2016 | glioblastoma | University Hospital, Toulouse | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FMISO | “FMISO (fluoromisonidazole), a radiopharmaceutical that directly assess tumor hypoxia using Positron Emission Tomography(PET)” NCT01246869 ↗4“The study drug, called FMISO, provides information about the oxygen levels in a tumor” NCT03649880 ↗ |
| Known as | [18F]-fluoromisonidazole | “1H-1-(3-[18F]-fluoro-2-hydroxy-propyl)-2-nitro-imidazole [18F]-fluoromisonidazole” NCT01246869 ↗ |
| Known as | fluoromisonidazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01246869 ↗ |
| Modality | Diagnostic / imaging agent | “Brain scan with radiopharmaceutical imaging tracer that directly assesses tumor hypoxia” NCT01246869 ↗ |
| Route | Intravenous | “Given IV” NCT03649880 ↗ |